BAL-0019764

BAL-0019764 is a small molecule monocyclic β-lactam that functions as a β-lactamase inhibitor. Developed by Naeja-RGM Pharmaceutical, a Canadian contract research organization, the compound was designed to address bacterial resistance by targeting and neutralizing β-lactamase enzymes. These enzymes are produced by certain bacteria to hydrolyze and deactivate β-lactam antibiotics, such as penicillins and cephalosporins. By inhibiting these enzymes, BAL-0019764 was intended to restore or enhance the efficacy of co-administered antibiotics against resistant bacterial strains. The drug was investigated for potential use in treating infectious diseases, including bacterial infections and acne vulgaris. However, development of BAL-0019764 has been discontinued.